Molecular Partners AG American Depositary Shares
MOLN Real Time Price USDRecent trades of MOLN by members of U.S. Congress
---
|
Name
|
Type
|
Shares
|
Price
|
Shares Held
|
Date
|
Reported
|
|---|
|
Investor
|
Shares
|
Change in Shares
|
Market Value
|
Date
|
Reported
|
|---|
|
Investor
|
Type
|
Shares
|
Change in Shares
|
Market Value
|
Date
|
Reported
|
|---|
Recently reported changes in MOLN holdings by institutional investors
Quarterly net insider trading by MOLN's directors and management
* Insider trading data parsed from SEC Form 4 filings by Quiver Quantitative. Sign up for the Quiver API for real-time access.
- 1M
- 3M
- 6M
- YTD
- 1Y
- 2Y
- 5Y
- MAX
About
Key Metrics
Return (1d)
Return (30d)
Return (1Y)
CAGR (Total)
Max Drawdown
Beta
Alpha
Sharpe Ratio
Win Rate
Average Win
Average Loss
Annual Volatility
Annual Std Dev
Information Ratio
Treynor Ratio
Total Trades
Metrics Definitions
Disclaimer: The performance results shown are based on historical backtesting and are hypothetical in nature. Backtested performance does not represent actual trading and does not account for all market factors that may affect execution, such as liquidity, slippage, and changing market conditions. Past performance is not necessarily indicative of future results. There is no guarantee that any trading strategy will be profitable or avoid losses.
-
Alpha
Measures a portfolio's risk-adjusted performance against that of its benchmark
Learn More about Alpha -
Annual Standard Deviation
Measures how much the portfolio's total return varies from its mean or average.
Learn More about Annual Standard Deviation -
Annual Volatility
A statistical measure of the dispersion of returns for the portfolio.
Learn More about Annual Volatility -
Average Win
The average return (%) for trades that resulted in a positive return.
-
Average Loss
The average return (%) for trades that resulted in a negative return.
-
Beta
A measure of the volatility of the portfolio compared to the market as a whole.
Learn More about Beta -
CAGR
CAGR (Compounded Annual Growth Rate), is the historical annualized rate of return for an investment strategy, throughout the backtest period.
Learn More about CAGR -
Information Ratio
A measurement of portfolio returns beyond the returns of its benchmark compared to the volatility of those returns.
Learn More about Information Ratio -
Max Drawdown
the maximum observed loss from a peak to a trough of a portfolio, before a new peak is attained.
Learn More about Max Drawdown -
Sharpe Ratio
The Sharpe Ratio is a measure of historical risk-adjusted return, which quantifies the amount of return that an investor received per unit of risk.
Learn More about Sharpe Ratio -
Total Trades
The total number of trades made by this strategy.
-
Treynor Ratio
Attempts to measure how successful an investment is in providing compensation to investors for taking on investment risk.
Learn More about Treynor Ratio -
Win Rate
The percentage of total trades that resulted in a positive return.
Be the first to see our newest insights and key updates across all datasets.
Government lobbying spending instances
Former government officials who have lobbied for MOLN
9 former government officials from 4 congressional offices at 6 lobbying firms have lobbied for MOLN, most recently Jul 20, 2023.
-
Alexander Hecht Senate New Chief Counsel, Senate Committee on Small Business & Entrepreneurship
-
Andrew Vogt Senate New Senate HELP Committee
-
Andrew Vogt Senate Health Professional Staff Member, Senate Health, Education, Labor, and Pensions Committee; Legislative Assistant, Senator Mark Kirk -
Al Simpson House 2011-2017 COS REP Mick Mulvaney; -
Rodney Frelinghuysen House New U.S. Congressman (1995 - 2019)
-
Tim Hutchinson Congress New U.S. Senator (97-03); U.S. Congressman (93-97)
-
Albert Wynn House New U.S. Congressman (92-08)
-
Clare Chmiel House New Rep. Doris Matsui, Scheduler
MOLN Estimated quarterly lobbying spending
MOLN Revenue by Segment or Geography
New MOLN patent grants
-
Patent Title: Designed ankyrin repeat domain with improved stability Oct. 14, 2025
-
Patent Title: Designed ankyrin repeat domains with altered surface residues Oct. 07, 2025
-
Patent Title: Multispecific proteins Jun. 17, 2025
-
Patent Title: Darpin based multi-specific t-cell engagers Dec. 05, 2023
-
Patent Title: Designed ankyrin repeat domains with altered surface residues Feb. 14, 2023
-
Patent Title: Ankyrin repeat binding proteins and their uses Oct. 11, 2022
-
Patent Title: Designed ankyrin repeat proteins binding to hepatocyte growth factor Sep. 27, 2022
-
Patent Title: Recombinant binding proteins and their use May. 17, 2022
-
Patent Title: Recombinant binding proteins targeting her2 and serum albumin, and their uses Jul. 21, 2020
-
Patent Title: Modified binding proteins inhibiting the vegf-a receptor interaction May. 12, 2020
-
Patent Title: Binding proteins comprising at least two repeat domains against her2 Aug. 06, 2019
-
Patent Title: Capping modules for designed ankyrin repeat proteins Jun. 18, 2019
-
Patent Title: Recombinant binding proteins and their use Dec. 18, 2018
-
Patent Title: Modified binding proteins inhibiting the vegf-a receptor interaction Dec. 26, 2017
-
Patent Title: Designed repeat proteins binding to serum albumin Oct. 03, 2017
-
Patent Title: Capping modules for designed ankyrin repeat proteins Aug. 01, 2017
-
Patent Title: Recombinant proteins that simultaneously bind hgf, vegf-a and serum albumin, comprising ankyrin repeat domains Oct. 04, 2016
-
Patent Title: Modified binding proteins inhibiting the vegf-a receptor interaction Mar. 22, 2016
-
Patent Title: Designed repeat proteins binding to serum albumin Mar. 15, 2016
-
Patent Title: Capping modules for designed ankyrin repeat proteins Dec. 29, 2015
-
Patent Title: Designed ankyrin repeat proteins binding to platelet-derived growth factor Oct. 20, 2015
-
Patent Title: Binding proteins inhibiting the vegf-a receptor interaction Dec. 02, 2014
-
Patent Title: Modified binding proteins inhibiting the vegf-a receptor interaction Apr. 29, 2014
Federal grants, loans, and purchases
Estimated quarterly amount awarded to MOLN from public contracts
Recent insights relating to MOLN
Recent picks made for MOLN stock on CNBC
ETFs with the largest estimated holdings in MOLN
- ... Highest Price Target
- ... Median Price Target
- ... Lowest Price Target
|
Analyst
|
Firm
|
Current
|
Previous
|
Date
|
|---|
- Is $MOLN stock a Buy, Sell, or Hold?
- What is the price target for $MOLN stock?
* Analyst consensus is not financial advice. Please see our data disclaimers .
|
Shareholder
|
Shares Held
|
|---|
- Who owns $MOLN stock?
- Who owns the most shares of $MOLN stock?
- What funds own $MOLN stock?
* These are estimates based on data taken from SEC filings. There may be inaccuracies due to parsing errors, accidental double-counting, incorrect classification of indirectly owned shares, or any other number of issues.
The Quiver Smart Score combines our data on Congress Trading, Lobbying, Insider Trading, CNBC Mentions and more to provide a comprehensive view of the strength of a stock's underlying data.
The Smart Score grades stocks on a scale of 1 (weakest) to 10 (strongest) based on the strength of the underlying data.Sign Up to view MOLN Smart Score
See concise summaries of analyst reports, presenting both bullish and bearish arguments for a stock.
Example:
The Bulls Say summary highlights positive aspects of the stock.
The Bears Say summary points out potential risks and negative aspects of the stock.
Molecular Partners AG is a clinical stage biopharmaceutical company. The Company has programs in various stages of pre-clinical and clinical development, with oncology as its main focus. The firm develops protein therapeutics called DARPin therapeutics for the treatment of serious diseases, including cancer and sight-threatening disorders. The company is currently focusing on oncology through their robust pipeline of clinical and preclinical programs, with particular attention to MP0712, the key Radio-DARPin candidate targeting DLL3 now in a Phase 1/2a trial in the United States.
Molecular Partners AG American Depositary Shares (MOLN) Historical Stock Prices
Daily open, high, low, close, adjusted close and volume for Molecular Partners AG American Depositary Shares (MOLN).
Quiver Premium charts MOLN's full daily history since 2014 with each congressional purchase and sale and every open-market insider purchase marked on the price line, with hover details for each trade.
Upgrade to Premium| Date | Open | High | Low | Close | Adj. Close | Volume |
|---|
Open, high, low and close are the prices as traded. Adjusted close accounts for splits and dividends, and is what the chart and returns use. Where a company changed its ticker, its history under the old symbol is included.
The Quiver API serves daily prices back to 2014 alongside congressional trades, insider trades, 13F holdings and lobbying, all under one key and inside Claude or ChatGPT through our MCP server.
Explore the Quiver APIWe estimate that -- received a compensation of -- in --, making them the highest paid executive at MOLN, per a recent SEC DEF 14A filing.
|
Name
|
Role
|
Salary
|
Bonus
|
Stock/Option Awards
|
Total Compensation
|
|---|